US FDA opens US market to Regeneron/Sanofi mCRC drug Zaltrap
This article was originally published in Scrip
Executive Summary
On schedule, the US FDA on 3 August approved Regeneron Pharmaceuticals’ concentrated form of aflibercept, which will be sold as Zaltrap, as an intravenous infusion treatment in combination with FOLFIRI chemotherapy for adults with metastatic colorectal cancer (mCRC) – giving the company a nice win after its disappointment earlier in the week with the rejection of its gout drug in the US.